Ascendis’ likely approval of TransCon CNP for achondroplasia poses a major threat to BioMarin’s best-selling drug. Read why I ...

As the S&P 500 reaches new highs amid optimism over trade deals and corporate earnings, investors are closely watching the tech sector, which continues to drive market momentum despite concerns about ...